#Aids2026: We analysed SA’s first LEN roll-out data. Here’s what we found
South Africa has more than half of all Africans using the world's newest HIV prevention injection. But the real story lies beyond the headline numbers. Bhekisisa analysed the health department's first six weeks of roll-out data to reveal who's choosing LEN, whether it's bringing new people onto HIV prevention and if the country has enough doses to keep up with demand. The post #Aids2026: We…
South Africa houses more than half of all Africa's users of the lenacapavir (LEN) six-monthly HIV prevention injection. However, the real insight lies in the data analysis of the health department's initial roll-out period. Bhekisisa examined the first six weeks of data to understand the demographics of those choosing LEN and the potential gaps in the program.
The health department began administering LEN at 360 government clinics across six provinces, representing about 10% of South Africa's public clinics. By the end of the six-week period, 98.5% of HIV-negative individuals given a choice between a daily HIV prevention pill and LEN opted for the twice-yearly injection. The majority of South Africa's LEN users are concentrated in Gauteng and KwaZulu-Natal, the provinces with the highest number of clinics offering the injection.
Health Minister Aaron Motsoaledi attributed the high acceptance of LEN to the public's realization of its value. LEN is important to note, as it is not a vaccine, despite some concerns about vaccine hesitancy following the COVID pandemic. The data reveals whether LEN is attracting first-time users of HIV prevention medication or simply replacing the daily pill, and it also examines if South Africa has enough donated doses to meet the growing demand before more affordable generic versions become available.
Written by urgent.news from Bhekisisa's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.
